| Document Type
|
:
|
BL
|
| Record Number
|
:
|
748273
|
| Doc. No
|
:
|
b568229
|
| Main Entry
|
:
|
L. Denis, (ed.).
|
| Title & Author
|
:
|
Antiandrogens in prostate cancer : : a key to tailored endocrine treatment\ L. Denis, (ed.).
|
| Publication Statement
|
:
|
Berlin ; New York : Springer, ©1996.
|
| Series Statement
|
:
|
Monographs (European School of Oncology)
|
| Page. NO
|
:
|
(120 pages) : illustrations
|
| ISBN
|
:
|
3642457452
|
|
|
:
|
: 9783642457456
|
| Contents
|
:
|
Introduction --; Some aspects of the molecular endocrinology of prostatic cancer --; Pharmacology of cyproterone acetate: a short review --; Cyproterone acetate: results of clinical trials and indications for use in human prostate cancer --; Biological properties of flutamide --; Combination therapy with flutamide: the therapy of choice from early to advanced stages of prostate cancer --; Casodex: preclinical studies --; Clinical aspects of casodex --; Pharmacodynamics and pharmacokinetics of nilutamide in animal and man --; A review of the clinical studies with nilutamide --; Indications for antiandrogen treatment in prostate cancer.
|
| Abstract
|
:
|
The introduction of maximal androgen blockade as a clinical therapy by Brachi and Labrie more than a decade ago led to a huge controversy on the clinical use of antiandrogens in the treatment of prostate cancer. Three consensus meetings were subsequently organized with the support of the American Cancer Society, the Urological Group of the European Organization for Research and Treatment of Cancer and the International Prostate Health Council. The first results of the meta-analysis of 22 trials did not put an end to the controversy, however, and clinicians were left confused by conflicting reports published by dozens of experts. The meeting behind the present volume created a forum for the scientists who developed the drugs and specialist clinicians to produce a consensus. The result is an overview of the field, condensed from hundreds of publications. The information has been updated to provide precise clinical indications for the use of antiandrogens in combination treatments and monotherapy for the individual patient. We hope that this team effort will facilitate ongoing discussions and lead to improved patient care as well as increased knowledge of the drugs that are so vital to our patients' quality of life and survival.
|
| Subject
|
:
|
Antiandrogens -- Therapeutic use.
|
| Subject
|
:
|
Prostate -- Cancer -- Chemotherapy.
|
| Subject
|
:
|
Prostatic Neoplasms -- drug therapy.
|
| LC Classification
|
:
|
RC280.P7L346 1996
|
| Added Entry
|
:
|
L Denis
|